This collaboration, which combines KaliVir's expertise in the development of oncolytic viruses with Astellas' capabilities in advanced drug development... Dec 07
CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma... Dec 07
Results showed that Hemlibra’s safety profile was consistent with previous observations and no new safety signals were observed after the longer follow-up... Dec 07
Antengene announces acceptance of IND application in China for ATG-010 (selinexor) in combination with R-GDP (SR-GDP) for the treatment of rrDLBCL in ... Dec 07
Sinovac expects to be able to manufacture 300 million doses annually and aims to complete the construction of a second production facility by the end ... Dec 07
-Advertisements-